Hsu YC - Search Results

1

Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.

Kim HS, Yu X, Kramer J, Thrift AP, Richardson P, Hsu YC, Flores A, El-Serag HB, Kanwal F. Kim HS, et al. Among authors: hsu yc. J Hepatol. 2022 Feb;76(2):294-301. doi: 10.1016/j.jhep.2021.09.009. Epub 2021 Sep 23. J Hepatol. 2022. PMID: 34563579 Free PMC article.

2

Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study.

Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Hsu YC, et al. Hepatology. 2012 Aug;56(2):698-705. doi: 10.1002/hep.25684. Epub 2012 Jul 6. Hepatology. 2012. PMID: 22378148

3

Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.

Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Hsu YC, et al. Hepatology. 2013 Jul;58(1):150-7. doi: 10.1002/hep.26300. Epub 2013 May 15. Hepatology. 2013. PMID: 23389758

4

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hsu YC, et al. Hepatology. 2014 Apr;59(4):1293-302. doi: 10.1002/hep.26892. Epub 2014 Feb 18. Hepatology. 2014. PMID: 24122848 Clinical Trial.

5

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.

Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, Lo GH, Perng DS, Lin JT, Mo LR. Hsu YC, et al. J Antimicrob Chemother. 2014 Jul;69(7):1920-7. doi: 10.1093/jac/dku041. Epub 2014 Feb 26. J Antimicrob Chemother. 2014. PMID: 24576950

6

Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study.

Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Wu CY, et al. Among authors: hsu yc. Gut. 2016 Apr;65(4):693-701. doi: 10.1136/gutjnl-2014-308786. Epub 2015 Feb 10. Gut. 2016. PMID: 25670811

7

Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma.

Hsu YC, Wu CY, Lin JT. Hsu YC, et al. Semin Oncol. 2015 Apr;42(2):329-38. doi: 10.1053/j.seminoncol.2014.12.023. Epub 2014 Dec 31. Semin Oncol. 2015. PMID: 25843737 Review.

8

Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients.

Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Hsu YC, et al. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1490-1498.e3. doi: 10.1016/j.cgh.2016.03.024. Epub 2016 Mar 24. Clin Gastroenterol Hepatol. 2016. PMID: 27018299

9

Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.

Hsu YC, Mo LR, Chang CY, Wu MS, Yang TH, Kao JH, Chen CC, Tseng CH, Tai CM, Lin CW, Wu CY, Lin JT. Hsu YC, et al. J Gastroenterol Hepatol. 2017 Aug;32(8):1512-1519. doi: 10.1111/jgh.13728. J Gastroenterol Hepatol. 2017. PMID: 28122151

10

Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.

Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, Wu CY. Lee TY, et al. Among authors: hsu yc. Clin Gastroenterol Hepatol. 2018 Jun;16(6):947-954.e4. doi: 10.1016/j.cgh.2017.09.031. Epub 2017 Sep 22. Clin Gastroenterol Hepatol. 2018. PMID: 28951229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,525 results

Search Page

Filters